Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-293-0 | CAS number: 137-42-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
- Justification for type of information:
- Data is from secondary source.
Data source
Referenceopen allclose all
- Reference Type:
- secondary source
- Title:
- Repeated dose inhalation Toxicity study of Metam-sodium in Rats .
- Author:
- European Commission
- Year:
- 2 000
- Bibliographic source:
- European Commission, European Chemicals Bureau, 2000
- Reference Type:
- secondary source
- Title:
- Repeated dose inhalation Toxicity study of Metam-sodium in Rats
- Author:
- US EPA
- Year:
- 1 994
- Bibliographic source:
- United states environment protection agency, 1994
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: As mention below
- Principles of method if other than guideline:
- To evaluate the toxicity of Metam Sodium in Sprague–Dawley male and female rats for subacute study.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Metam-sodium
- EC Number:
- 205-293-0
- EC Name:
- Metam-sodium
- Cas Number:
- 137-42-8
- Molecular formula:
- C2H5NS2.Na
- IUPAC Name:
- sodium (methylcarbamothioyl)sulfanide
- Test material form:
- solid: crystalline
- Details on test material:
- - Name of test material : Metam-sodium
- Molecular formula : C2H4NNaS2
- Molecular weight : 129.1826 g/mol
- Smiles notation : C(=S)(NC)[S-].[Na+]
- InChl : 1S/C2H5NS2.Na/c1-3-2(4)5;/h1H3,(H2,3,4,5);/q;+1/p-1
- Substance type: Organic
- Physical state: Solid
Constituent 1
- Specific details on test material used for the study:
- - Name of test material : Metam-sodium
- Molecular formula : C2H4NNaS2
- Molecular weight : 129.1826 g/mol
- Smiles notation : C(=S)(NC)[S-].[Na+]
- InChl : 1S/C2H5NS2.Na/c1-3-2(4)5;/h1H3,(H2,3,4,5);/q;+1/p-1
- Substance type: Organic
- Physical state: Solid
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- not specified
- Vehicle:
- not specified
- Details on inhalation exposure:
- Not specified
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- Not specified
- Duration of treatment / exposure:
- 3 weeks
- Frequency of treatment:
- daily – 4 hours per day
Doses / concentrations
- Remarks:
- 0.51, 1.54 and 4.53 mg/l
- No. of animals per sex per dose:
- 0.51, 1.54 and 4.53 mg/l
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Not specified
Examinations
- Observations and examinations performed and frequency:
- Observations and examinations performed & frequency
CAGE SIDE OBSERVATIONS: Not specified.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily
BODY WEIGHT: Not specified .
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Not specified - Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Not specified
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not specified
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: At the end of
the study ophthalmology l was performed.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of
the study hematology was performed.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of the study clinical chemistry was performed.
URINALYSIS: Yes
- Time schedule for collection of urine: At the end of the study urinalysis was performed.
NEUROBEHAVIOURAL EXAMINATION: Not specified - Sacrifice and pathology:
- Sacrifice and pathology
GROSS PATHOLOGY: Yes, At the end of the study gross–pathological examinations were performed.
HISTOPATHOLOGY: Yes , At the end of the study
histological examinations were performed. - Statistics:
- Not specified
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- During 21 days of treatment with the test substance no influence on the animals was seen at the low dose level (0.51 mg/l)
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- The treated animals being exposed to the highest dose (4.53 mg/l) 1 female and 10 males died during the study. No mortality observed in control.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At the medium dosage (1.54 g/l) body weight gain of both sexes in treated group was markedly inhibited compare to control .
At the high dosage (4.53 mg/l) body weight gain was markedly diminished) in treated group compare to control. - Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At the medium dosage (1.54 g/l) hemoglobin content in male and female and the number of leukocytes were
increased (only females) in treated group was markedly inhibited compare to control.
At the high dosage (4.53 mg/l) hemoglobin content,
erythrocyte–and platelet count in blood were increased.
Leucocytes and reticulocytes were slightly reduced in treated group compare to control. - Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- At the medium dosage (1.54 g/l) Organ weights (except adrenals of the males) were reduced) in treated group was markedly inhibited compare to control.
At the high dosage (4.53 mg/l) the weighed internal organs showed markedly reduced absolute values, whereas relative lung weight was increased - Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- At the medium dosage (1.54 g/l) histopathological examinations showed pulmonary lesions (alveolar emphysema) in treated group was markedly inhibited compare to control.
At the high dosage (4.53 mg/l) microscopic examination showed multiple pulmonary lesions, thymic atrophy, hyperplasia and depletion, inhibited spermiogenesis, atrophic prostate, tracheitis, changes in the urinary bladder and inflammatory, partly purulent, degenerations in the nasal cavity, maxillary sinus and meatus which might be due to the treatment. - Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 0.51 other: mg/l
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant effct were observed at this dose
- Remarks on result:
- other: No toxic effct were observed
Target system / organ toxicity
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- NOAEL was considered to be 0.51 mg/l for Metam Sodium in Sprague–Dawley male and female rats for subacute study by inhalation route.
- Executive summary:
Repeated dose inhalation study ofMetam Sodium was assessed for its possible toxic nature.For this purpose subacute study was conducted on Sprague–Dawley male and female rats by using test substance at the concentration of0.51, 1.54 and 4.53 mg/l. The test substance was exposed daily – 4 hours per day for 3 weeks. The animals were observed for mortality, clinical chemistry, body weight, hematology, organ weight histopathology and gross pathology. Significant effect were observed at the medium dosage (1.54 g/l) and high dosage (4.53 mg/l) . During 21 days of treatment with the test substance no influence on the animals was seen at the low dose level (0.51 mg/l). Therefore NOAEL was considered to be 0.51 mg/l forMetam Sodium in Sprague–Dawley male and female rats for subacute study by inhalation route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.